Dose intensification in hormone receptor-negative and/or human epidermal growth factor receptor 2-negative high-risk primary breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 7, 2012, Pages 758-

  De Giorgi, Ugo ^a   Amadori, Dino ^a  

^a Istituto Tumori Romagna   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; DOSE CALCULATION; FOLLOW UP; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS;

EID: 84857531638     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.7257     Document Type: Letter

References (7)

1. Berry DA, Ueno NT, Johnson MM, et al: High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: Overview of 15 randomized trials. J Clin Oncol 29:3214-3223, 2011
2. Hryniuk WM, Peters WP, Ragaz J: Determinants of outcome in adjuvant chemotherapy of breast cancer: Dose intensity versus total dose versus dose size. Breast Cancer Res Treat 64:66, 2000 (abstr 66)
3. Bonilla L, Ben-Aharon I, Vidal L, et al: Dose-dense chemotherapy in nonmetastatic breast cancer: A systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 102:1845-1854, 2010
4. Gluz O, Nitz UA, Harbeck N, et al: Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: Results of WSG AM-01 trial. Ann Oncol 19:861-870, 2008 (Pubitemid 351649186)
5. Rodenhuis S, Bontenbal M, van Hoesel QG, et al: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 17:588- 596, 2006
6. Gluz O, Mengele K, Schmitt M, et al: Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapy. J Clin Oncol 27:6144-6151, 2009
7. Diallo-Danebrock R, Ting E, Gluz O, et al: Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dosedense chemotherapy. Clin Cancer Res 13:488-497, 2007 (Pubitemid 46225354)